W
LGND icon

Wealthfront’s Ligand Pharmaceuticals LGND Stock Holding History

Wealthfront’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-109
Closed -$6K – 712
2015
Q3 		$6K Buy
109
+82
+304% +$4.97K ﹤0.01% 1076
2015
Q2 		$2K Buy
+27
New +$1.47K ﹤0.01% 1183

Other funds holding LGND

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wealthfront's LGND Position: Q4 2015 in Review

Wealthfront sold out of Ligand Pharmaceuticals (LGND) in Q4 2015, closing a stake of 109 shares — an estimated $6K sold.

Wealthfront first reported a position in LGND in Q2 2015 and held it in 2 quarters. The position peaked at $6K in Q3 2015. 233 funds tracked by Wall St. Rank hold LGND as of Q4 2015.

  • Wealthfront reported no remaining Ligand Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Wealthfront sold 109 Ligand Pharmaceuticals shares in Q4 2015, an estimated $6K.
  • Wealthfront first reported a position in Ligand Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Wealthfront's Ligand Pharmaceuticals position peaked at $6K in Q3 2015.
  • 233 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2015.

Based on Wealthfront's 13F filing for Q4 2015, filed 17 Feb 2016.